phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»10.24411/2587-7836-2019-10040phkinetica-87Research ArticleОБЗОРЫREVIEWSМатриксные металлопротеиназы и их ингибиторыMatrix metalloproteinases and their inhibitorsГригоркевичОксана СергеевнаGrigorkevichO. S.oksana.grigorkevich@acaaempharm.ruМокровГригорий ВладимировичMokrovG. V.noemail@neicon.ruКосоваЛюбовь ЮрьевнаKosovaL. Yu.noemail@neicon.ruФГБНУ «НИИ фармакологии имени В.В. Закусова»РоссияFSBI «Zakusov Institute of Pharmacology»Russian FederationРХТУ им. Д.И. МенделееваРоссияD. Mendeleev University of Chemical Technology of RussiaRussian Federation20190602201902316Copyright © Григоркевич О.С., Мокров Г.В., Косова Л.Ю., 20192019Григоркевич О.С., Мокров Г.В., Косова Л.Ю.Grigorkevich O.S., Mokrov G.V., Kosova L.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/87

В 1962 г. Gross J и Lapierre C впервые была обнаружена металлопротеиназа. С тех пор было охарактеризовано более 20 ферментов этого семейства, а также подробно изучены их функции. Металлопротеиназы учавствуют в регуляции кровяного давления, развитии и ремоделировании клеточного матрикса, обезболивании, рассеянном склерозе, процессе свертывания крови, заживления ран, в процессах опухолевой трансформации и метастазирования и др. Настоящий обзор посвящён рассмотрению представлений о структуре матриксных металлопротеиназ, механизме их действия, а так же эндогенным и экзогенным ингибиторам матриксных металлопротеиназ. Особый акцент сделан на анализе подходов к дизайну синтетических ингибиторов матриксных металлопротеиназ и их активности. Представленный обзор демонстрирует перспективность конструирования новых селективных ингибиторов матриксных металлопротеиназ.

Metalloproteinase was discovered by Gross and Lapierre in 1962 for the first time. Since then, more than 20 enzymes of this family have been characterized, and their functions have been studied in detail. Metalloproteinases take part in blood pressure regulation, the cell matrix extension and remodeling, anesthesia, multiple sclerosis, blood coagulation, wound healing, tumor transformation and metastasis, etc. This review covers structure of matrix metalloproteinases, their mechanism of action, as well as MMP's endogenous and exogenous inhibitors. A special place is occupied by analysis of approaches to matrix metalloproteinases synthetic inhibitors and their activity. This review demonstrates the perspectivity of new selective matrix metalloproteinase inhibitors design.

протеиназыметаллопротеиназыматриксные металлопротеиназыММПтканевые ингибиторы матриксных металлопротеиназингибиторы матриксных металопротеиназproteinasesmetalloproteinasesmatrix metalloproteinasesMMPtissue inhibitors of matrix metalloproteinasesinhibitors of matrix metalloproteinasesРабота поддержана грантом Российского Фонда Фундаментальных исследований № 18-015-00244 А.ReferencesRivera S, Khrestchatisky M, Kaczmarek L, et al. Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology? Journal of Neuroscience. 2010;30(46):15337–15357. DOI: https://doi.org/10.1523/ JNEUROSCI.3467-10.2010Rivera S, Khrestchatisky M, Kaczmarek L, et al. Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology? Journal of Neuroscience. 2010;30(46):15337–15357. DOI: https://doi.org/10.1523/ JNEUROSCI.3467-10.2010Gupta SP. Quantitative StructureαActivity Relationship Studies on Zinc-Containing Metalloproteinase Inhibitors. Chemical Reviews. 2007;107(7):3042–3087. DOI: 10.1021/cr030448tGupta SP. Quantitative StructureαActivity Relationship Studies on Zinc-Containing Metalloproteinase Inhibitors. Chemical Reviews. 2007;107(7):3042–3087. DOI: 10.1021/cr030448tVerma RP, Hansch С. Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q)SARs. Bioorganic & Medicinal Chemistry. 2007;5:2223-2268. DOI: 10.1016/j.bmc.2007.01.011Verma RP, Hansch С. Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q)SARs. Bioorganic & Medicinal Chemistry. 2007;5:2223-2268. DOI: 10.1016/j.bmc.2007.01.011Ярмолинская М.И., Молотков А.С., Денисова В.М. Матриксные металлопротеиназы и ингибиторы: классификация, механизм действия // Журнал акушерства и женских болезней. – 2012. – Т. 61. – № 1. – С. 113–125. [Yarmolinskaya MI, Molotkov AS, Denisova VM. Matriksnye metalloproteinazy i ingibitory: klassifikatsiya, mekhanizm deistviya. Zhurnal akusherstva i zhenskikh boleznei. 2012;61(1):113-125. (In Russ).]Ярмолинская М.И., Молотков А.С., Денисова В.М. Матриксные металлопротеиназы и ингибиторы: классификация, механизм действия // Журнал акушерства и женских болезней. – 2012. – Т. 61. – № 1. – С. 113–125. [Yarmolinskaya MI, Molotkov AS, Denisova VM. Matriksnye metalloproteinazy i ingibitory: klassifikatsiya, mekhanizm deistviya. Zhurnal akusherstva i zhenskikh boleznei. 2012;61(1):113-125. (In Russ).]МаркеловаЕ.В., ЗдорВ.В., РоманчукА.Л. идр. Матриксные металлопротеиназы: их взаимосвязь с системой цитокинов, диагностический и прогностический потенциал // Иммунология, аллергология, инфектология. – 2016. – № 2. – С. 11–22. [Markelova EV, Zdor VV, Romanchuk AL, et al. Matriksnye metalloproteinazy: ikh vzaimosvyaz' s sistemoi tsitokinov, diagnosticheskii i prognosticheskii potentsial. Immunologiya, allergologiya, infektologiya. 2016;2:11–22. (In Russ).]МаркеловаЕ.В., ЗдорВ.В., РоманчукА.Л. идр. Матриксные металлопротеиназы: их взаимосвязь с системой цитокинов, диагностический и прогностический потенциал // Иммунология, аллергология, инфектология. – 2016. – № 2. – С. 11–22. [Markelova EV, Zdor VV, Romanchuk AL, et al. Matriksnye metalloproteinazy: ikh vzaimosvyaz' s sistemoi tsitokinov, diagnosticheskii i prognosticheskii potentsial. Immunologiya, allergologiya, infektologiya. 2016;2:11–22. (In Russ).]Zitka O, Kukacka J, Krizkova S, et al. Matrix Metalloproteinases. Current Medicinal Chemistry. 2010;17(31):3751–3768. DOI: 10.2174/092986710793213724Zitka O, Kukacka J, Krizkova S, et al. Matrix Metalloproteinases. Current Medicinal Chemistry. 2010;17(31):3751–3768. DOI: 10.2174/092986710793213724Woessner JF. The family of matrix metalloproteinases. Ann. NY Acad. Sci. 1994;732:11–21.Woessner JF. The family of matrix metalloproteinases. Ann. NY Acad. Sci. 1994;732:11–21.Supuran CT, Winum J, editors. Drug desighn of zinc-enzyme inhibitors. 1st ed. Hoboken: Wiley; 2009.Supuran CT, Winum J, editors. Drug desighn of zinc-enzyme inhibitors. 1st ed. Hoboken: Wiley; 2009.Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie. 2005;87:249–263. DOI: https:// doi.org/10.1016/j.biochi.2004.11.019Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie. 2005;87:249–263. DOI: https:// doi.org/10.1016/j.biochi.2004.11.019СоловьёваН.И. Основныеметаллопротеиназысоединительнотканногоматрикса // Биоорганическаяхимия. – 1994. – Т. 20. – № 2. – С. 143–152. [Solov'eva NI. Osnovnye metalloproteinazy soedinitel'notkannogo matriksa. Bioorganicheskaya khimiya. 1994;20(2):143–152. (In Russ).]СоловьёваН.И. Основныеметаллопротеиназысоединительнотканногоматрикса // Биоорганическаяхимия. – 1994. – Т. 20. – № 2. – С. 143–152. [Solov'eva NI. Osnovnye metalloproteinazy soedinitel'notkannogo matriksa. Bioorganicheskaya khimiya. 1994;20(2):143–152. (In Russ).]Butler GS. The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily. J. Biol. Chem. 2004;279(15):15615-15620. DOI:10.1074/jbc. m312727200Butler GS. The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily. J. Biol. Chem. 2004;279(15):15615-15620. DOI:10.1074/jbc. m312727200Lauer-Fields JI, Juska D, Fields GB. Matrix metalloproteinases and collagen metabolism. Biopolimers. 2002;66(1):19-32. DOI: 10.1002/bip.10201Lauer-Fields JI, Juska D, Fields GB. Matrix metalloproteinases and collagen metabolism. Biopolimers. 2002;66(1):19-32. DOI: 10.1002/bip.10201Iyer RP, Patterson NL, Fields GB, et al. The History of Matrix Metalloproteinases (MMPs): Milestones, Myths, and (Mis)Perceptions. Am. J. Physiol. Heart Circ Physiol. 2012:17. DOI: 10.1152/ajpheart.00577.2012Iyer RP, Patterson NL, Fields GB, et al. The History of Matrix Metalloproteinases (MMPs): Milestones, Myths, and (Mis)Perceptions. Am. J. Physiol. Heart Circ Physiol. 2012:17. DOI: 10.1152/ajpheart.00577.2012Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem. Bio. 1996;3(11):895–904. DOI: http://dx.doi.org/10.1016/S1074-5521(96)90178-7Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem. Bio. 1996;3(11):895–904. DOI: http://dx.doi.org/10.1016/S1074-5521(96)90178-7Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochemical pharmacology. 2008;75:346–359. DOI:10.1016/j.bcp.2007.07.004Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochemical pharmacology. 2008;75:346–359. DOI:10.1016/j.bcp.2007.07.004Huxley-Jones J, Clarke TK, Beck C. The evolution of the vertebrate metzincins; Insights from Ciona intestinalis and Danio rerio. BMC Evol. Biol. 2007;7(1):63. DOI: 10.1186/1471-2148-7-63Huxley-Jones J, Clarke TK, Beck C. The evolution of the vertebrate metzincins; Insights from Ciona intestinalis and Danio rerio. BMC Evol. Biol. 2007;7(1):63. DOI: 10.1186/1471-2148-7-63Шадрина А.С. Матриксные металлопротеиназы: структура, функции и генетический полиморфизм // Патогенез. – 2017. – Т. 15. – № 2. – С. 14–23. [Shadrina AS. Matriksnye metalloproteinazy: struktura, funktsii i geneticheskii polimorfizm. Patogenez. 2017;15(2):14–23. (In Russ).] DOI: 10.25557/GM.2017.2.7297Шадрина А.С. Матриксные металлопротеиназы: структура, функции и генетический полиморфизм // Патогенез. – 2017. – Т. 15. – № 2. – С. 14–23. [Shadrina AS. Matriksnye metalloproteinazy: struktura, funktsii i geneticheskii polimorfizm. Patogenez. 2017;15(2):14–23. (In Russ).] DOI: 10.25557/GM.2017.2.7297Клишо Е.В. Матриксные металлопротеиназы в онкогенезе // Сибирский онкологический журнал. – 2003. – № 2 – С. 62–70. [Klisho EV. Matriksnye metalloproteinazy v onkogeneze. Sibirskii onkologicheskii zhurnal. 2003;2:62–70. (In Russ).]Клишо Е.В. Матриксные металлопротеиназы в онкогенезе // Сибирский онкологический журнал. – 2003. – № 2 – С. 62–70. [Klisho EV. Matriksnye metalloproteinazy v onkogeneze. Sibirskii onkologicheskii zhurnal. 2003;2:62–70. (In Russ).]Stack MS, Itoh Y, Young TN, et al. Fluorescence quenching studies of matrix metalloproteinases (MMPs): evidence for structural rearrangement of the proMMP-2/TIMP-2 complex upon mercurial activation. Arch. Biochem. Biophys. 1996;333(1):163–169. DOI: 10.1006/abbi.1996.0377Stack MS, Itoh Y, Young TN, et al. Fluorescence quenching studies of matrix metalloproteinases (MMPs): evidence for structural rearrangement of the proMMP-2/TIMP-2 complex upon mercurial activation. Arch. Biochem. Biophys. 1996;333(1):163–169. DOI: 10.1006/abbi.1996.0377Kim TH, Mars WM. Expression and Activation of Pro-MMP-2 and Pro-MMP-9 During Rat Liver Regeneration. Hepatology. 2003;31(1):75–82. DOI: 10.1002/hep.510310114Kim TH, Mars WM. Expression and Activation of Pro-MMP-2 and Pro-MMP-9 During Rat Liver Regeneration. Hepatology. 2003;31(1):75–82. DOI: 10.1002/hep.510310114Woessner JF, Jr. MMPs and TIMPs - An Historical Perspective. Mol Biotechnol. 2002;22(1):33-49. DOI: 10.1385/MB:22:1:033 22. Kim WU, Min SY, Cho ML, et al. Elevated matrix metalloproteinase 9 in patients with systemic Sclerosis. Arthritis Res. 2005;7(1):71–79. DOI: 10.1186/ar1454Woessner JF, Jr. MMPs and TIMPs - An Historical Perspective. Mol Biotechnol. 2002;22(1):33-49. DOI: 10.1385/MB:22:1:033 22. Kim WU, Min SY, Cho ML, et al. Elevated matrix metalloproteinase 9 in patients with systemic Sclerosis. Arthritis Res. 2005;7(1):71–79. DOI: 10.1186/ar1454Yu WH, Yu S, Meng Q, et al. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. Biol Chem. 2000;275:31226–31232. DOI: 10.1074/jbc.M000907200Yu WH, Yu S, Meng Q, et al. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. Biol Chem. 2000;275:31226–31232. DOI: 10.1074/jbc.M000907200Hundsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer. 2005:11(6):849–860.Hundsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer. 2005:11(6):849–860.Whittaker M, Ayscought A. Matrix metalloproteinases and their inhibitors – current status and future challenges. Celltransmissions. 2001;17(1):3–14.Whittaker M, Ayscought A. Matrix metalloproteinases and their inhibitors – current status and future challenges. Celltransmissions. 2001;17(1):3–14.Schechter I, Berger A. Reprint of «On the size of the active site in proteases. I. Papain». Biochem. Biophys. Res. Communs. 2012;425(3):497–502. DOI: 10.1016/j.bbrc.2012.08.015Schechter I, Berger A. Reprint of «On the size of the active site in proteases. I. Papain». Biochem. Biophys. Res. Communs. 2012;425(3):497–502. DOI: 10.1016/j.bbrc.2012.08.015Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: `Embracing the MMP-independent-side of the family`. J. Mol. Cell. Cardiol. 2010;48(3):445–453. DOI: 10.1016/j.yjmcc.2009.09.013Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: `Embracing the MMP-independent-side of the family`. J. Mol. Cell. Cardiol. 2010;48(3):445–453. DOI: 10.1016/j.yjmcc.2009.09.013Fingleton B. Matrix Metalloproteinases as Valid Clinical Targets Current Pharmaceutical Design. Curr. Pharm. Des. 2007;13(3):333-346. DOI: 10.2174/138161207779313551Fingleton B. Matrix Metalloproteinases as Valid Clinical Targets Current Pharmaceutical Design. Curr. Pharm. Des. 2007;13(3):333-346. DOI: 10.2174/138161207779313551Thomas NV, Kim SK. Metalloproteinase Inhibitors: Status and Scope from Marine Organisms. Biochemistry Research International. 2010;2010:1–10. DOI:10.1155/2010/845975Thomas NV, Kim SK. Metalloproteinase Inhibitors: Status and Scope from Marine Organisms. Biochemistry Research International. 2010;2010:1–10. DOI:10.1155/2010/845975Lindsey ML, Ma Y, Yabluchanskiy A. Matrix Metalloproteinase-9 Post Myocardial Infarction: Breakdowns and Breakthroughs. Global J. Hum. Anat. Physiol. Res. 2014;1(1):6–9.Lindsey ML, Ma Y, Yabluchanskiy A. Matrix Metalloproteinase-9 Post Myocardial Infarction: Breakdowns and Breakthroughs. Global J. Hum. Anat. Physiol. Res. 2014;1(1):6–9.Whittaker M, Floyd CD, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999;99(9):2735–2776. DOI. 10.1021/cr9804543.Whittaker M, Floyd CD, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999;99(9):2735–2776. DOI. 10.1021/cr9804543.Levin JI. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TAC. Curr. Top. Med. Chem. 2004;4(12):1289–1310. DOI. 10.2174/1568026043387935Levin JI. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TAC. Curr. Top. Med. Chem. 2004;4(12):1289–1310. DOI. 10.2174/1568026043387935PharmaXChange.info [Internet]. Matrix Metalloproteinases: Its Implications in Cardiovascular Disorders [updated November 28, 2011]. Available from: http://pharmaxchange.info/press/2011/11/matrixmetalloproteinases-its-implications-in-cardiovascular-disorders/PharmaXChange.info [Internet]. Matrix Metalloproteinases: Its Implications in Cardiovascular Disorders [updated November 28, 2011]. Available from: http://pharmaxchange.info/press/2011/11/matrixmetalloproteinases-its-implications-in-cardiovascular-disorders/Graff von Roedern E, Grams R, Brandstetter H, et al. Design and Synthesis of Malonic Acid-Based Inhibitors of Human Neutrophil Collagenase (MMP8). J. Med. Chem. 1998;41(3):339–345. DOI: 10.1021/jm9706426Graff von Roedern E, Grams R, Brandstetter H, et al. Design and Synthesis of Malonic Acid-Based Inhibitors of Human Neutrophil Collagenase (MMP8). J. Med. Chem. 1998;41(3):339–345. DOI: 10.1021/jm9706426Preece G, Murphy G, Agers A. Metalloproteinase-mediated Regulation of L-selectin Levels on Leucocytes. J Biol Chem. 1996;771(20):11634–11640. DOI: 10.1074/jbc.271.20.11634Preece G, Murphy G, Agers A. Metalloproteinase-mediated Regulation of L-selectin Levels on Leucocytes. J Biol Chem. 1996;771(20):11634–11640. DOI: 10.1074/jbc.271.20.11634Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix Metalloproteinase Inhibitors: A Review on Pharmacophore Mapping and (Q)Sars Results. Current Medicinal Chemistry. 2005;12(3):339–355. DOI:10.2174/0929867053363243Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix Metalloproteinase Inhibitors: A Review on Pharmacophore Mapping and (Q)Sars Results. Current Medicinal Chemistry. 2005;12(3):339–355. DOI:10.2174/0929867053363243Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 2006;69:677–687. DOI:10.1016/j.cardiores.2005.11.032Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 2006;69:677–687. DOI:10.1016/j.cardiores.2005.11.032Veerendhar A, Reich R, Breuer E. Phosphorus based inhibitors of matrix metalloproteinases. Comptes Rendus Chimie. 2010;13(8–9):1191–1202. DOI. 10.1016/j.crci.2010.07.003Veerendhar A, Reich R, Breuer E. Phosphorus based inhibitors of matrix metalloproteinases. Comptes Rendus Chimie. 2010;13(8–9):1191–1202. DOI. 10.1016/j.crci.2010.07.003Bender SL, Melwin AA. Metalloproteinase inhibitors, pharmaceutical composition containing them and their pharmaceutical compositions. United States patent US 5985900. 1999. Nov 16.Bender SL, Melwin AA. Metalloproteinase inhibitors, pharmaceutical composition containing them and their pharmaceutical compositions. United States patent US 5985900. 1999. Nov 16.Kim SH, Pudzianowski AT, Leavitt KJ, et al. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005;15(4):1101–1106. DOI:10.1002/chin.200526096Kim SH, Pudzianowski AT, Leavitt KJ, et al. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005;15(4):1101–1106. DOI:10.1002/chin.200526096Wang J, Medina C, Radomski MW, et al. N-subsitutedhomopiperazine barbiturates as gelatinase inhibitors. Bioorg. Med. Chem. 2011;19(16):4985–4999. DOI:10.1016/j.bmc.2011.06.055Wang J, Medina C, Radomski MW, et al. N-subsitutedhomopiperazine barbiturates as gelatinase inhibitors. Bioorg. Med. Chem. 2011;19(16):4985–4999. DOI:10.1016/j.bmc.2011.06.055Wang J, O’Sullivan S, Harmon S, et al. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem. 2012;55(5):2154–2162. DOI:10.1021/jm201352kWang J, O’Sullivan S, Harmon S, et al. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. J Med Chem. 2012;55(5):2154–2162. DOI:10.1021/jm201352kWang J, Radomski MW, Medina C, et al. MMP inhibition by barbiturate homodimers. Bioorg Med Chem Lett. 2013;23(2):444–447. DOI:10.1016/j.bmcl.2012.11.063Wang J, Radomski MW, Medina C, et al. MMP inhibition by barbiturate homodimers. Bioorg Med Chem Lett. 2013;23(2):444–447. DOI:10.1016/j.bmcl.2012.11.063Yue Zhong, Yu-Ting Lu, Ying Sun, et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opinion on Drug Discovery. 2017;13(1):75–87. DOI: 10.1080/17460441.2018.1398732Yue Zhong, Yu-Ting Lu, Ying Sun, et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opinion on Drug Discovery. 2017;13(1):75–87. DOI: 10.1080/17460441.2018.1398732Jillian M Cathcart, Jian Cao. MMP Inhibitors: Past, present and future. Frontiers in Bioscience. 2015;20(7):1164–1178. DOI:10.2741/4365Jillian M Cathcart, Jian Cao. MMP Inhibitors: Past, present and future. Frontiers in Bioscience. 2015;20(7):1164–1178. DOI:10.2741/4365Song J, Peng P, Chang J, et al. Selective non-zinc binding MMP-2 inhibitors: novel benzamide Ilomastat analogs with anti-tumor metastasis. Bioorg Med Chem Lett. 2016;26(9):2174–2178. DOI:10.1016/j.bmcl.2016.03.064.Song J, Peng P, Chang J, et al. Selective non-zinc binding MMP-2 inhibitors: novel benzamide Ilomastat analogs with anti-tumor metastasis. Bioorg Med Chem Lett. 2016;26(9):2174–2178. DOI:10.1016/j.bmcl.2016.03.064.clinicaltrials.gov [Internet]. BB-2516 [update 2004 May 26; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/ results?cond=&term=BB-2516&cntry=&state=&city=&distclinicaltrials.gov [Internet]. BB-2516 [update 2004 May 26; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/ results?cond=&term=BB-2516&cntry=&state=&city=&distHidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93(3):178–193. DOI:10.1093/jnci/93.3.178Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93(3):178–193. DOI:10.1093/jnci/93.3.178clinicaltrials.gov [Internet]. A Phase 1 Study of S-3304 in Patients With Solid Tumors [update 2002 Apr 10; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00033215?cond=matrix+metallo proteinase&draw=10&rank=55clinicaltrials.gov [Internet]. A Phase 1 Study of S-3304 in Patients With Solid Tumors [update 2002 Apr 10; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00033215?cond=matrix+metallo proteinase&draw=10&rank=55clinicaltrials.gov [Internet]. Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer [update 2004 Feb 26; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/nct00078390clinicaltrials.gov [Internet]. Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer [update 2004 Feb 26; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/nct00078390clinicaltrials.gov [Internet]. A Phase I Study of Oral COL-3 (NSC683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic [update 1999 Nov 4; cited 2018 Aug 17]. Available from: https:// clinicaltrials.gov/ct2/show/NCT00001683?cond=matrix+metalloproteina se&draw=4&rank=20clinicaltrials.gov [Internet]. A Phase I Study of Oral COL-3 (NSC683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic [update 1999 Nov 4; cited 2018 Aug 17]. Available from: https:// clinicaltrials.gov/ct2/show/NCT00001683?cond=matrix+metalloproteina se&draw=4&rank=20Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992;31(31):7152–-7154. DOI:10.1021/bi00146a017Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 1992;31(31):7152–-7154. DOI:10.1021/bi00146a017Beckett RP, Whittaker M. Matrix metalloproteinase inhibitors 1998. Expert Opin Ther Pat. 1998;8(3):259–282. DOI.org/10.1517/13543776.8.3.259Beckett RP, Whittaker M. Matrix metalloproteinase inhibitors 1998. Expert Opin Ther Pat. 1998;8(3):259–282. DOI.org/10.1517/13543776.8.3.259clinicaltrials.gov [Internet]. Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling (TIPTOP) [update 2007 May 4; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00469261?cond=matrix+metalloproteinase&draw=10&rank=54clinicaltrials.gov [Internet]. Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling (TIPTOP) [update 2007 May 4; cited 2018 Aug 17]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00469261?cond=matrix+metalloproteinase&draw=10&rank=54clinicaltrials.gov [Internet]. A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin [update 2018 Mar 29; cited 2018 Aug 17]. Available from: https:// clinicaltrials.gov/ct2/show/NCT03481972?term=Doxycicline&rank=1clinicaltrials.gov [Internet]. A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin [update 2018 Mar 29; cited 2018 Aug 17]. Available from: https:// clinicaltrials.gov/ct2/show/NCT03481972?term=Doxycicline&rank=1

The authors declare that there are no conflicts of interest present.